Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sonnet BioTherapeutics Holdings ( (SONN) ) has issued an update.
On January 28, 2025, Sonnet BioTherapeutics announced that the European Patent Office granted a patent for its FHAB technology, which includes therapeutic fusion proteins for tumor targeting and extended pharmacokinetics. This EU patent, effective until 2038, significantly expands Sonnet’s global intellectual property portfolio, which now includes coverage in China, Japan, Russia, and New Zealand. The patent strengthens Sonnet’s market position by providing expanded global protection and differentiation from competitors. This development is seen as a milestone that validates the company’s FHAB platform, enhancing its competitive edge in the biotechnology industry.
More about Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company specializing in targeted biologic drugs with single or bifunctional action. The company has developed a proprietary platform known as FHAB (Fully Human Albumin-Binding), which uses a fully human single chain antibody fragment to bind to human serum albumin for efficient transport to target tissues. This technology is designed to specifically target tumor and lymphatic tissue, improving the safety and efficacy of immune modulating biologic drugs. Sonnet’s lead program, SON-1010, is under development for solid tumors and ovarian cancer, while other programs like SON-1210 and SON-080 are also in progress for different cancer and neuropathy treatments.
YTD Price Performance: 13.12%
Average Trading Volume: 1,487,561
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.5M
For detailed information about SONN stock, go to TipRanks’ Stock Analysis page.
